The effectiveness of rosuvastatin and atorvastatin on goal attainment in patients included in the STARSHIP trial at high risk for CHD (LDL-C <100 mg/dL) are displayed on the current slide.

All treatments brought a majority of patients to NCEP ATP III LDL-C goals.1

Reference:

1. Lloret, R et al.  Comparison of rosuvastatin versus atorvastatin in Hispanic-American patients with hypercholesterolemia (from the STARSHIP trial). American Journal of Cardiology. 2006;98:768-773.